Effects of a Gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation

Effects of a Gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation: a randomized, double-blinded, placebo-controlled, multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN30426947

Enrollment

100

Registered

2010-04-30

Start date

2009-05-19

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysmenorrhea (menstrual pain) caused by blood stagnation Urological and Genital Diseases Pain and other conditions associated with female genital organs and menstrual cycle

Interventions

Patients will be randomised to receive: 1. Gyejibongnyeong-hwan, a Korean herbal remedy consisting of Cinnamomi ramulus, Poria, Moutan cortex, Persicae semen (peach seed) and Paeoniae radix. 1200 mg/

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Female aged 18 to 35 years 2. Women with a period cycle of 30 ± 3 days during last 3 months 3. Women who have menstrual pain (dysmenorrhea) over 6 degrees by Visual Analogue Scale (VAS) 4. Women who are diagnosed with blood stagnation by two oriental medical gynaecologic specialists 5. Given written informed consent form 6. Given written informed consent form of genetic study

Exclusion criteria

Exclusion criteria: 1. Women who have major neuro-psychiatric disorder or have history of major neuro-psychiatric disorder (schizophrenia, epilepsy, alcohol abuse, anorexia etc) 2. Women who are planning to have baby or do not agree to use appropriate contraception (oral pill, hormone contraception, intrauterine device, condom etc) 3. Women who are taking anti-depressant, anti-serotonin barbiturate, psychotropic drugs

Design outcomes

Primary

Measure	Time frame
Pain, assessed by Visual Analogue Scale (VAS), measured at screening, baseline and weeks 4, 8, 12 and 20	—

Secondary

Measure	Time frame
1. Blood Stagnation Scale (based on Korean Medicine), measured at screening, baseline and weeks 4 and 8 2. Quantity of pain killer pills during period, recorded at screening, baseline and weeks 4, 8, 12 and 20 3. Short Form McGill Pain Questionnaire, measured at screening, baseline and weeks 4, 8, 12 and 20 4. Cox Menstrual Symptom Scale, measured at screening, baseline and weeks 4, 8, 12 and 20 5. Heart rate variability (HRV) outcome, measured at screening, baseline and weeks 4 and 8	—

Measure

Time frame

1. Blood Stagnation Scale (based on Korean Medicine), measured at screening, baseline and weeks 4 and 8 2. Quantity of pain killer pills during period, recorded at screening, baseline and weeks 4, 8, 12 and 20 3. Short Form McGill Pain Questionnaire, measured at screening, baseline and weeks 4, 8, 12 and 20 4. Cox Menstrual Symptom Scale, measured at screening, baseline and weeks 4, 8, 12 and 20 5. Heart rate variability (HRV) outcome, measured at screening, baseline and weeks 4 and 8

—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 27, 2026